"Enzyme Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
Descriptor ID |
D004791
|
MeSH Number(s) |
D27.505.519.389
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Enzyme Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Enzyme Inhibitors".
This graph shows the total number of publications written about "Enzyme Inhibitors" by people in this website by year, and whether "Enzyme Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 0 | 1 |
1995 | 12 | 10 | 22 |
1996 | 11 | 19 | 30 |
1997 | 11 | 24 | 35 |
1998 | 12 | 23 | 35 |
1999 | 17 | 31 | 48 |
2000 | 18 | 32 | 50 |
2001 | 27 | 48 | 75 |
2002 | 26 | 55 | 81 |
2003 | 48 | 70 | 118 |
2004 | 29 | 57 | 86 |
2005 | 24 | 53 | 77 |
2006 | 25 | 43 | 68 |
2007 | 34 | 43 | 77 |
2008 | 15 | 45 | 60 |
2009 | 19 | 31 | 50 |
2010 | 16 | 16 | 32 |
2011 | 22 | 11 | 33 |
2012 | 12 | 26 | 38 |
2013 | 12 | 10 | 22 |
2014 | 14 | 13 | 27 |
2015 | 17 | 11 | 28 |
2016 | 18 | 10 | 28 |
2017 | 17 | 11 | 28 |
2018 | 12 | 15 | 27 |
2019 | 8 | 9 | 17 |
2020 | 16 | 10 | 26 |
2021 | 13 | 10 | 23 |
2022 | 3 | 10 | 13 |
2023 | 2 | 7 | 9 |
To return to the timeline,
click here.
Below are the most recent publications written about "Enzyme Inhibitors" by people in Profiles.
-
DHODH: a promising target in the treatment of T-cell acute lymphoblastic leukemia. Blood Adv. 2023 11 14; 7(21):6685-6701.
-
Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors. Science. 2023 09 08; 381(6662):eabn4180.
-
A novel small molecule inhibitor of p38? MAP kinase augments cardiomyocyte cell cycle entry in response to direct cell cycle stimulation. Br J Pharmacol. 2023 12; 180(24):3271-3289.
-
ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer. Future Oncol. 2023 Jul; 19(23):1577-1591.
-
Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma. Haematologica. 2023 06 01; 108(6):1616-1627.
-
Targeting Glutamine Metabolism with a Novel Na+/K+-ATPase Inhibitor RX108 in Hepatocellular Carcinoma. Mol Cancer Ther. 2023 06 01; 22(6):693-705.
-
Nonresponse to Heart?Failure?Therapy: An Important Trajectory. JACC Heart Fail. 2023 06; 11(6):729-732.
-
Phase 1b study of pan-AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA/AKT/PTEN-mutated advanced solid tumors. Cancer. 2023 06 15; 129(12):1919-1929.
-
Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations. Blood Cancer J. 2023 02 17; 13(1):27.
-
Therapeutic Response in Pediatric Neuromyelitis Optica Spectrum Disorder. Neurology. 2023 02 28; 100(9):e985-e994.